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Abstract Venous thromboembolism (VTE) is a serious
and often fatal medical condition with an increasing inci-
dence. Despite the changing landscape of VTE treatment
with the introduction of the new direct oral anticoagulants
many uncertainties remain regarding the optimal use of
traditional parenteral agents. This manuscript, initiated by
the Anticoagulation Forum, provides clinical guidance
based on existing guidelines and consensus expert opinion
where guidelines are lacking. This specific chapter ad-
dresses the practical management of heparins including
low molecular weight heparins and fondaparinux. For each
anticoagulant a list of the most common practice related
questions were created. Each question was addressed using
a brief focused literature review followed by a multidisci-
plinary consensus guidance recommendation. Issues
addressed included initial anticoagulant dosing recom-
mendations, recommended baseline laboratory monitoring,
managing dose adjustments, evidence to support a rela-
tionship between laboratory tests and meaningful clinical
outcomes, special patient populations including extremes
of weight and renal impairment, duration of necessary
parenteral therapy during the transition to oral therapy,
candidates for outpatient treatment where appropriate and
management of over-anticoagulation and adverse effects
including bleeding and heparin induced thrombocytopenia.
This article concludes with a concise table of clinical
management questions and guidance recommendations to
provide a quick reference for the practical management of
heparin, low molecular weight heparin and fondaparinux.
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Introduction
Heparin has been a component of the initial treatment of
venous thromboembolism (VTE) for decades. Despite its
long history, various aspects of the practical use of
unfractionated heparin (UFH), whether delivered intra-
venously (IV) or subcutaneously (SC), continue to chal-
lenge clinicians. In 1998, the US FDA approved the low
molecular weight heparin (LWMH) enoxaparin (Lovenox)
for VTE treatment, followed by approval of the synthetic
heparin-like compound fondaparinux (Arixtra) in 2004. In
2007, the LMWH dalteparin (Fragmin) was approved for
VTE treatment in patients with cancer. These agents,
intended for subcutaneous administration, offer practical
advantages over unfractionated heparin, yet present their
own challenges, particularly in special populations. This
chapter will address the practical use and management of
the parenteral heparin anticoagulants available in the US
when used in the treatment of VTE.
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Methods
To provide guidance on the practical management of the
heparin anticoagulants in adults, we first developed a
number of pivotal practical questions pertaining to each of
the commonly used heparin compounds (UFH, LMWH and
fondaparinux) to be reviewed in this document (Table 1).
Questions were developed by consensus from the authors.
The literature addressing the above questions was reviewed
by searching electronic databases (PubMed, Medline) and
the authors’ personal libraries, with a focus on high quality
cohort studies and randomized controlled trials published
in the last 10 years, where available. For each question, a
brief summary and interpretation of pertinent literature and
existing guidelines, where available, are provided, fol-
lowed by guidance to the reader.
Guidance
Heparin for the treatment of acute VTE
(1) How should heparin be initiated, including baseline
laboratory tests and dosing?
While heparin therapy for VTE treatment is typically
administered by continuous IV infusion, both adjusted dose
and fixed dose SC injections can also be utilized. A com-
parative study of SC and IV heparin using the same initial
dose (5000 unit IV bolus followed by 30,000 units/day)
reported an increased risk of VTE recurrence with SC
heparin (19.3 % vs. 5.2 %; p = 0.024), suggesting the
need for higher doses with this route [1]. A meta-analysis
comparing IV heparin to dose-adjusted SC heparin (initial
dose 5000 units IV then 17,500 units SC twice daily) for
Table 1 Guidance questions to be considered
Heparin for treatment of acute VTE
(1) How should heparin be initiated, including baseline laboratory tests and dosing?
(2) What weight should be used to calculate dosing, and should obese and low body weight patients be treated differently?
(3) How should heparin be monitored?
(4) What data support the benefit of monitoring?
(5) What is the appropriate therapeutic range?
(6) When should heparin resistance be suspected?
(7) What algorithm should be used for dosing adjustments?
(8) What is the appropriate duration of therapy for heparin for transition to oral anticoagulant therapy?
(9) How should heparin-induced over-anticoagulation, thrombocytopenia and bleeding be managed?
LMWH for treatment of acute VTE
(1) How should LMWH be initiated, including baseline laboratory tests and dosing?
(2) What weight should be used to calculate dosing, and should obese and low body weight patients be treated differently?
(3) How should patients with renal impairment be treated?
(4) How should routine treatment be monitored?
(5) Is there a role for peak anti-Xa monitoring and for trough anti-Xa monitoring?
(6) What is the appropriate duration of therapy when transitioning to oral anticoagulant therapy?
(7) Which patients are acceptable candidates for outpatient treatment of VTE with LMWH?
(8) How should LMWH-induced over-anticoagulation, thrombocytopenia and bleeding be managed?
Fondaparinux for treatment of acute VTE
(1) How should fondaparinux be initiated, including baseline labs and dosing?
(2) What weight should be used to calculate dosing, and should obese and low body weight patients be treated differently?
(3) How should patients with renal impairment be treated?
(4) How should treatment be monitored?
(5) Is there a role for peak anti-Xa monitoring and for trough anti-Xa monitoring?
(6) What is the appropriate duration of therapy when transitioning to oral anticoagulant therapy?
(7) Who is a candidate for outpatient treatment of VTE with fondaparinux?
(8) Can fondaparinux be used for VTE treatment in the presence of active heparin-induced thrombocytopenia (HIT) or those with a history
of HIT?
(9) How should fondaparinux-induced over-anticoagulation and bleeding be managed?
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initial DVT treatment found a lower risk of VTE recur-
rence or extension with SC heparin (relative risk [RR] 0.62,
95 % confidence interval [CI] 0.39–0.98) with a similar
risk of major bleeding (RR 0.79, 95 % CI 0.42–1.48) [2].
Prandoni et al. conducted an open label multicenter trial in
720 patients comparing LMWH to adjusted dose SC hep-
arin in those with acute, symptomatic VTE. SC heparin
regimens were weight based with those over 70 kg
receiving an initial 6000 unit IV bolus then 17,500 units
twice daily. Objectively confirmed recurrent VTE, major
bleeding and overall mortality were similar [3]. In the fixed
dose heparin investigators (FIDO) trial, a randomized, open
label, non-inferiority trial, fixed dose heparin (333 units/kg
bolus then 250 units/kg every 12 h) was compared to
LWMH for initial treatment of acute VTE [4]. There was
no weight exclusion for the trial. Recurrent VTE at
3 months occurred in 3.8 % of heparin patients compared
to 3.4 % of LMWH patients (absolute difference 0.4 %;
95 % CI -2.6 to 3.3 %) while major bleeding occurred in
1.1 % of heparin patients versus 1.4 % of LMWH patients
(absolute difference, -0.3 %; 95 % confidence interval,
-2.3 to 1.7 %).
The optimal initial dosing of continuous infusion hep-
arin therapy is controversial. In 1989, the second American
College of Chest Physicians (ACCP) Clinical Practice
Guideline on VTE treatment recommended an initial 5000
unit bolus followed by a 1000 unit/h infusion [5]. In 1993,
Raschke et al. compared weight based heparin dosing (80
units/kg followed by 18 units/kg/h) to a standard regimen
(5000 units followed by 1000 units/h) in 115 patients with
venous or arterial thrombosis [6]. A five-fold reduction in
recurrent VTE was observed with weight-based dosing
(95 % CI 1.1–21.9). Nevertheless, most VTE treatment
trials incorporated a fixed dose initial heparin infusion
regimen of 5000 unit bolus followed by infusion of
approximately 1300 units/h [7]. In 1992, the ACCP VTE
treatment guidelines suggested a 5000–10,000 unit bolus
followed by a fixed heparin infusion of 1300 units/h
(31,200 units/day) and in 1995 and 2004 they endorsed
either a fixed regimen or the Raschke weight based regi-
men [8–10]. For a 70 kg patient, the Raschke regimen
translates into a heparin bolus of 5600 units followed by
infusion of 1260 units/h. The 2012 version of the guideli-
nes do not address UFH dosing in the VTE treatment
chapter [11]. However, in the chapter on parenteral anti-
coagulants, UFH dosing recommendations are similar to
those in 1995 and include either a weight based regimen
(Raschke regimen) or a fixed regimen of 5000 unit bolus
followed by a continuous infusion of at least 32,000 uni-
ts/day [12].
The Joint Commission’s National Patient Safety Goals
require that a written policy stating required baseline and
ongoing laboratory tests for patients on heparin be in place
in healthcare institutions [13]. Pre-treatment hemoglobin
and hematocrit are used as a baseline from which to assess
subsequent changes that may reflect bleeding. A baseline
platelet count is used to compare to subsequent values in
order to detect the possible development of heparin-in-
duced thrombocytopenia (HIT). Finally, an elevated pre-
treatment prothrombin time (PT) or activated partial
thromboplastin time (aPTT) may detect the presence of an
underlying coagulation defect.
Guidance Statement We suggest that total body weight,
CBC, PT and aPTT be obtained prior to initiating heparin
therapy. Heparin efficacy is related to dose regardless of
route. The initial dose is more important than the aPTT in
predicting efficacy. Although optimal initial dosing for
bolus and continuous infusion remain uncertain, we sug-
gest doses outlined in Table 2, acknowledging that these
options have not been compared in head-to-head clinical
trials. Internal audits to determine the dose requirement to
produce therapeutic anticoagulation based upon the
responsiveness of the health-system’s aPTT reagent and
coagulation instrument are strongly encouraged.
(2) What weight should be used to calculate dosing and
should obese and low body weight patients be trea-
ted differently?
The volume of distribution of heparin approximates
blood volume, is related to body weight and averages
Table 2 Recommended initial dosing for UFH in VTE treatment
Route Reference Bolus dose Maintenance dose
Continuous infusion
Fixed dose Hull et al. [1] 5000 units 1250–1280 units/ha
Weight based Raschke et al. [6] 80 units/kg 18 units/kg/h
Subcutaneous
Fixed dose Kearon et al. [4] 333 units/kg 250 units/kg every 12 h
Adjusted dose Prandoni et al. [3] 5000 units 17,500 units every 12 h adjusted to aPTT
a Caution is needed with low body weight patients; individualized dosing should be considered
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60 mL/kg [14]. There are no prospective trials evaluating
heparin dosing regimens using different weight strategies,
although a trial in obese patients (NCT01361193) is
ongoing. Current dosing recommendations do not specify
which weight should be used. The Raschke nomogram
used actual body weight; however only 9/115 patients
(\8 %) had a weight above 100 kg (range 101–131 kg) [6].
For the obese and morbidly obese patient, the impor-
tance of striking a balance between achieving effective
anticoagulation and avoidance of bleeding is apparent.
Although obese patients have a larger blood volume, the
vascularity of adipose tissue is lower than that of lean body
mass, raising concern for over-anticoagulation when hep-
arin is dosed using total body weight. Under-dosing is also
a concern as obese patients are at increased risk of VTE
recurrence. Dose caps employed to increase safety may
increase the risk of under-dosing in the obese/morbidly
obese patient and contribute to treatment failures.
Heparin dosing in obesity/morbid obesity has recently
been reviewed [15]. Current data are limited by the low
quality of evidence (case report, case series, retrospective
reports), the lack of a standard definition of obesity and the
small number of patients evaluated. Patient management
strategies include dosing based on total body weight, ideal
body weight, adjusted body weight, or total body weight
with a reduced infusion rate. Protocols based on total body
weight increase the risk of a supra-therapeutic aPTT;
however no increase in bleeding has been reported [16].
Heparin infusion rates resulting in therapeutic anticoagu-
lation have ranged from 5 to 12.8 units/kg/h in the
obese/morbidly obese population [14]. Definitive conclu-
sions as to which weight should be used cannot be drawn
due to the low quality of evidence in this area. As for
underweight patients, there are no data evaluating the most
appropriate heparin dosing but such patients may be at
increased bleeding risk [17].
Guidance Statement When a weight based heparin
dosing strategy is selected, we suggest total body weight
for calculating dose. For the obese/morbidly obese patient
either total body weight or adjusted body weight can be
used. Although no increased risk of major bleeding has
been reported when morbidly obese patients are managed
using total body weight, studies have not included patients
weighing above 270 kg. If adjusted body weight is used,
prompt attention to initial laboratory results is warranted
to ensure the therapeutic threshold is exceeded in a timely
manner. Empiric dose caps may increase the risk of initial
under anticoagulation in obese and morbidly obese
patients. If empiric dose caps are used, individualized
initial dosing should be available for obese and morbidly
obese patients.
(3) How should heparin be monitored?
The aPTT, which measures the function of the intrinsic
and common clotting pathways, is the most commonly
used laboratory test to monitor heparin. Numerous vari-
ables impact the aPTT result including pre-analytic (sam-
ple collection and processing), analytic (reagent and
instrument) and biologic factors (level of clotting factors)
[18]. Over 300 different reagent-instrument combinations
are used clinically. A therapeutic heparin level (0.3–0.7
u/mL) by anti-factor Xa (anti-Xa) analysis can produce
aPTT ratios ranging from 1.6–2.7 to 3.7–6.2 times control
depending upon the reagent/coagulometer combination
[11]. In response to the numerous limitations of the aPTT,
researchers have evaluated direct heparin concentration
monitoring using heparin anti-Xa levels. Compared to the
aPTT, the heparin anti-Xa level is less impacted by bio-
logic variables, but pre-analytic and analytic variability
remain and can be considerable [19]. The anti-Xa is also
more expensive than the aPTT, and is both less available
and less familiar to clinicians.
A recent review identified the potential advantages of
the heparin anti-Xa level over the aPTT for heparin mon-
itoring. Advantages included fewer monitoring tests, fewer
dose changes and a shorter time to obtain therapeutic
anticoagulation [20]. Large VTE trials evaluating patient
outcomes with heparin anti-Xa level monitoring are not
available. Although both the aPTT and the anti-Xa level
can be used to monitor heparin, paired results within
individual patients are often discordant [21]. In a recent
trial in which clinical outcomes of aPTT versus anti-Xa
monitoring were evaluated, a disproportionate prolongation
of the aPTT relative to the anti-Xa level was the most
common discordant pattern [22]. Patients with relatively
high aPTT to anti-Xa levels had higher rates of major
bleeding and death compared to patients with concordant
paired test results. National guidelines for heparin moni-
toring recognize the limitations of both approaches without
recommending a preferred approach [23].
Direct anti-Xa level monitoring is recommended in
those with heparin resistance (see subsequent section),
baseline aPTT elevation from a lupus anticoagulant or
contact factor deficiency or those with markedly elevated
levels of fibrinogen or factor VIII [24].
Guidance Statement The optimal approach to heparin
monitoring is unknown. Either aPTT or heparin anti-Xa
level monitoring may be used. We suggest using anti-Xa
level monitoring in patients with heparin resistance, a
prolonged baseline aPTT or altered heparin responsive-
ness. We suggest the aPTT or anti-Xa level be checked
every 6 h until two consecutive therapeutic results are
168 M. A. Smythe et al.
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obtained, after which the frequency of monitoring can be
extended to once daily.
(4) What data support the benefit of monitoring?
Monitoring aPTT
Despite the standard practice to monitor heparin through
coagulation laboratory testing, the body of evidence sup-
porting monitoring is surprisingly weak. In 1972, Basu
et al. reported a lower rate of VTE recurrence when the
aPTT was maintained between 1.5–2.5 9 control [25]. A
subsequent study using a rabbit model of thrombosis
demonstrated prevention of thrombus extension with an
aPTT of approximately 1.5 times control [26]. These data
provided the foundation for an empiric aPTT therapeutic
range of 1.5–2.5 times control. Over the next two decades,
important concepts emerged, which challenged the accep-
ted aPTT therapeutic range as well as the overall benefit of
monitoring heparin therapy. Data supporting a relationship
between sub-therapeutic aPTTs within the first 24–48 h
and increased VTE recurrence at 90 days came from post
hoc analysis of studies using fixed dose heparin regimens
of B30,000 units/day [7]. A pooled analysis of trials using
initial heparin infusion regimens of at least 30,000 uni-
ts/day showed no association between sub-therapeutic
aPTT and increased VTE recurrence (90 day recurrence:
6.3 % with sub-therapeutic aPTT in first 24–48 h versus
7 % in those with therapeutic aPTTs; odds ratio 0.89, 95 %
CI: 0.2–4) [27]. In the FIDO trial of unmonitored SC
heparin, recurrent VTE (at 90 days) occurred in 3.8 % of
heparin patients versus 3.4 % with LMWH, absolute risk
difference 0.4 (95 % CI -2.6 to 3.3) [4]. Although therapy
was unmonitored, on day 3 an aPTT was drawn and sub-
sequently analyzed by a central laboratory at study con-
clusion. None of the heparin patients with recurrent VTE
had a sub-therapeutic aPTT [4]. Data supporting the upper
limit of the heparin aPTT therapeutic range for VTE are
even weaker than data supporting the lower limit [7, 27–
30]. Hull et al. reported bleeding events in 8.6 % of VTE
patients with supratherapeutic aPTTs compared to 12.3 %
of patients without [28]. In the FIDO trial none of the
major bleeding events in the heparin group were associated
with an aPTT above 85 s [4].
Monitoring heparin levels
Protamine sulfate titration and anti-Xa analysis are two
approaches to heparin level monitoring. Early animal
studies suggested a heparin level therapeutic range of
0.2–0.4 units/mL by protamine sulfate titration [18]. Sub-
sequent studies from McMaster University demonstrated
that this range was equivalent to a heparin anti-Xa level of
approximately 0.3–0.7 units/mL [31]. This equivalency
between assay systems was promoted by national
guidelines despite data challenges to its validity [12, 24].
Since appearing in national guidelines, the heparin anti-Xa
level therapeutic range of 0.3–0.7 unit/mL has gained
widespread acceptance despite limited clinical trial out-
come data [31]. In 2008, the ACCP VTE treatment
guidelines stated ‘‘When patients are treated with an initial
heparin infusion of 1250 U/h (corresponding to 30,000
U/d) or 18 units/kg/hr, it is uncertain if adjustment of
heparin dose in response to the aPTT or heparin levels
improves efficacy or safety [32]. There are no recent trials
evaluating unmonitored continuous infusion heparin ther-
apy or different levels of heparin anticoagulation.
Guidance Statement The benefit of monitoring IV
heparin once a therapeutic threshold has been exceeded is
not well defined. We suggest monitoring of continuous
infusion heparin therapy, either using aPTT or anti-Xa, as
this is considered standard of care despite the weak evi-
dence base. Monitoring is optional in those receiving SC
weight-based heparin therapy.
(5) What is the appropriate therapeutic range?
The Raschke study, the pivotal trial for weight based IV
heparin dosing, used a fixed therapeutic aPTT interval of
46–79 s which corresponded to an aPTT ratio of 1.5–2.3
times control [6]. Other VTE treatment trials comparing
heparin to LMWH employed a fixed aPTT ratio of 1.5–2.5
times control for heparin patients. In recognition of the
variable sensitivity of different aPTT reagents to heparin, the
use of an empiric fixed interval or fixed aPTT ratio for
heparin monitoring is no longer recommended for treatment
of VTE in national guidelines. The College of American
Pathologists (CAP) and the ACCP recommend that each
institution define its own therapeutic aPTT range based upon
the responsiveness of the aPTT reagent and coagulometer in
use [12, 23, 24]. The therapeutic range should be re-estab-
lished with each change of reagent manufacturer, lot or
coagulation instrument. Ex-vivo samples (as opposed to
spiked samples) from 30 patients receiving therapeutic dose
heparin should be used. A 3.2 % sodium citrate concentra-
tion is recommended for sampling. Two approaches are
acceptable according to the CAP. The first is to use linear
regression analysis to determine the aPTT interval which
corresponds to a therapeutic heparin concentration (e.g.
0.3–0.7 anti-Xa units/mL). Although this approach was
previously recommended by the ACCP, the most recent
guidelines do not specify a desired therapeutic range for use
of heparin in the treatment of VTE [11, 12, 32]. The use of a
heparin concentration-calibrated aPTT therapeutic range for
heparin monitoring has not been prospectively evaluated
against alternative monitoring strategies.
The second approach recommended by the CAP com-
pares aPTT results using the old and new reagent and
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assesses reagent drift using the cumulative summation
method. Differences in aPTT results are tracked yearly and
adjustments in therapeutic range are needed when the
cumulative difference exceeds 7 s [24]. The CAP recom-
mends the first approach to establish the initial heparin
therapeutic range and the cumulative summation method
for subsequent changes in reagent. If direct heparin con-
centration monitoring is used, a therapeutic range of
0.3–0.7 U/mL by anti-Xa analysis is widely accepted and
promoted despite limited data [18, 24, 31, 33].
Guidance Statement The optimal heparin therapeutic
range is uncertain. The target therapeutic range is less impor-
tant than ensuring an appropriate initial heparin dose. TheCAP
suggests the one-time establishment of a heparin concentration-
derived aPTT therapeutic range. The cumulative summation
method is suggested for range re-evaluation following reagent/
instrument change. When anti-Xa monitoring is used, a thera-
peutic target of 0.3–0.7 units/mL is suggested.
(6) When should heparin resistance be suspected?
Heparin resistance is a term used to describe patients who
require high doses of heparin. Heparin resistance can be
caused by antithrombin deficiency, increased heparin
clearance or increased heparin binding proteins (often con-
sidered acute phase reactants). Patients with these conditions
have a reduction in the formation of heparin-antithrombin
complexes and require higher heparin doses to reach a
therapeutic aPTT. Although the term heparin resistance is
also used to describe patients with increased levels of factor
VIII or fibrinogen, these individuals maymore appropriately
be described as having altered heparin responsiveness. These
patients have a downward shift in the dose response curve
resulting in a shortened or blunted aPTT response. Such
patients may appear to be heparin resistant but increasing the
heparin dose based upon the aPTT may lead to over-anti-
coagulation and an increased risk of bleeding [34].
Heparin resistance is commonly defined as a daily dose in
excess of 35,000 units/day [31, 33]. This may be an inap-
propriately low threshold, as a dose of 19 units/kg/h for an
80 kg patient would exceed this daily dose. A weight based
definition of resistance (units/kg/h) may bemore appropriate
but consensus is lacking. In a study of ‘‘heparin resistant’’
(requiring[35,000 units/day) patients, Levine et al. com-
pared anti-Xa monitoring to aPTT monitoring. Patients
randomized to aPTT monitoring required higher heparin
doses while those randomized to anti-Xa level monitoring
had subtherapeutic aPTTs during the majority of treatment.
Rates of major bleeding and thrombosis were similar [35].
Guidance Statement We suggest drawing a paired
aPTT and heparin anti-Xa level when heparin resistance is
suspected. If the aPTT is subtherapeutic and the anti-Xa
level is therapeutic, the heparin dose does not require
adjustment and subsequent monitoring should occur using
the anti-Xa level when feasible. If, despite serial dose
increases, both the aPTT and anti-Xa level remain low,
true heparin resistance may be present.
(7) What algorithm should be used for dosing
adjustments?
The use of a nomogram to guide heparin dosage
adjustment increases the proportion of patients receiving
adequate anticoagulation based on achieving a therapeutic
aPTT [35]. Even with nomograms, however, nonthera-
peutic aPTTs occur in more than 25 % of patients in
clinical trials [36]. In one study, only 29 % of patients with
a therapeutic aPTT had two consecutive repeat therapeutic
aPTTs [37]. Dose adjustment algorithms can be weight
based (e.g. increase infusion rate by 2 units/kg/h) or fixed
dose (e.g. increase infusion rate by 100 units/h) [6, 38].
Dose adjustment algorithms were not provided in the major
VTE treatment trials comparing heparin to LMWH. A fixed
dose algorithm may be inadequate in obese patients [15]. In
a single center study, Cruickshank et al. evaluated the
performance of a dosage adjustment nomogram by calcu-
lating the success rate for each heparin dose adjustment
recommendation based upon the aPTT interval (e.g.
increase heparin infusion by 80 units/h for an aPTT of
50–59 s) [38]. Results were used to modify the dosage
adjustment algorithm. No studies are available which
compare different heparin dosage adjustment algorithms.
Health-systems typically adopt a published algorithm from
a single center trial [6, 39].
Guidance Statement We suggest that heparin dosing be
guided by a dose adjustment nomogram, and that a weight
based heparin dose adjustment algorithm may offer benefit
over a fixed adjustment algorithm for the obese patient.
More research in defining and assessing the optimal
dosage adjustment nomogram is needed.
(8) What is the appropriate duration of therapy for
transition to oral anticoagulant therapy?
Patients with VTE who are treated with a vitamin K
antagonist alone have an unacceptably high rate of VTE
extension and recurrence [40]. The ACCP recommendations
for the desired duration of overlap of a parenteral agent with
warfarin over the past 15 years are summarized in Table 3
[10, 11, 32, 41]. The current recommendation is to continue
parenteral anticoagulation along with warfarin for a mini-
mum of 5 days and until the INR is 2.0 or above for at least
24 h [11]. The 5 day minimum is recommended to avoid a
potential hypercoagulable state upon warfarin initiation.
Factor II levels take a minimum of 5 days to fall while
protein C (an endogenous anticoagulant) has a short half-life
and is more rapidly depleted [42]. The recommendation for
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an INR of 2 or greater for at least 24 h is provided to ensure
that the INR elevation indicates adequate anticoagulation
and not solely a reduction in factor VII (short half-life). The
ACCP recommended duration of overlap was followed in
some VTE treatment trials demonstrating similar efficacy of
LMWH to heparin (new VTE at 90 days in heparin patients
1.9 and 4.1 %) while others included a 6 day overlap with a
single INR requirement above 2.0 (recurrent 90 day VTE in
heparin patients 6.8 and 6.9 %) [28, 43–45]. In a retro-
spective study conducted in an academic medical center,
Hylek et al. reported compliance with the ACCP recom-
mendation for overlap in only 20 % of patients with more
than 40 % of surgical patients having less than a 4 day
overlap [37]. For hospitalized patients this recommendation
is often perceived to increase length of stay. Patients may be
discharged on LMWH to complete the requisite period of
overlap, but this temporary measure complicates the tran-
sition of care.
It is important to note that the ACCP recommendation
for an INR[ 2 for at least 24 h is paired with the rec-
ommendation to treat with a parenteral agent for at least
5 days (a separate level of evidence does not exist for the
INR recommendation). Recently, there is noticeable
movement away from requiring the INR to be above 2 for
at least 24 h. The 2015 Joint Commission VTE Core
Measures (VTE-3) address anticoagulant overlap require-
ments [46]. Compliance requires a minimum of 5 days of
overlap with a heparin product and warfarin (or discharge
on both agents or documentation of why overlap is not
indicated) and a single INR above 2 prior to discontinua-
tion of parenteral therapy. This approach has been used in
recent clinical trials [47].
Dabigatran, edoxaban, rivaroxaban and apixaban are
FDA approved for the treatment of VTE. These target-
specific oral anticoagulants (TSOACs) achieve their anti-
coagulant effect within 2–3 h of oral administration [48].
Nevertheless, when dabigatran or edoxaban are used for
VTE treatment, they must be started after a minimum of
5 days of parenteral anticoagulant therapy, according to
manufacturer recommendations based on study design [47,
49, 50].
The direct acting Xa inhibitors rivaroxaban and apixa-
ban do not require initial injectable therapy, but many
patients in the clinical trials did receive an initial dose of a
parenteral anticoagulant [51–53].
Recommendations for transitioning from parenteral to
oral anticoagulants are described in Table 4.
Guidance Statement Parenteral anticoagulation with
heparin should be overlapped with warfarin for at least
5 days and until a single INR is 2.0 or greater. Treatment
of VTE with rivaroxaban and apixaban does not require
initial parenteral anticoagulation while dabigatran and
edoxaban require a minimum of 5 days of parenteral
anticoagulation prior to initiation. See Table 4 for addi-
tional details.
(9) How should heparin-induced over-anticoagulation,
thrombocytopenia and bleeding be managed?
The rate of heparin-associated major bleeding is 3 % in
recent VTE treatment trials and increases to 4.8 % in a
real world practice setting [37, 54]. Failure to follow a
dosage adjustment algorithm may increase bleeding risk.
When major bleeding occurs and reversal of heparin’s
effect is desired, protamine sulfate can be administered. A
dose of 1 mg of protamine per 100 units of heparin is
recommended. Because of its relatively short half–life,
only heparin administered over the past few hours should
be considered in calculating the dose of protamine [54]. In
emergent situations, clinicians can typically administer
25 mg of protamine for those on continuous infusion
therapy with repeat dosing if needed. Protamine has its
own significant side effects including allergic reactions,
hypotension, bradycardia and respiratory toxicity. Pro-
tamine must be given by slow IV infusion at doses
B5 mg/min.
HIT is a paradoxical adverse effect of heparin which can
result in life threatening thrombosis. HIT is suspected more
often than the diagnosis is confirmed and over-treatment is
a growing concern. Once suspected, a 4 T score (Timing,
Thrombocytopenia, Thrombosis, Other) should be calcu-
lated to evaluate the likelihood of HIT [55]. In those with a
Table 3 History of ACCP recommendations for overlapping parenteral anticoagulants with warfarin for the treatment of VTE
Year VTE recommendation Level of evidence
2001
[41]
Treat with heparin or LMWH for at least 5 days and overlap with heparin or LMWH for at
least 4–5 days
1A (in comparison to
treatment for 10 days)
2004
[10]
Initiate vitamin K antagonist with LMWH or heparin on day one and discontinue heparin when




Treat with LMWH, heparin or fondaparinux for at least 5 days and until the INR is C2 for 24 h 1C
2012
[11]
Recommend early initiation of vitamin K antagonist (same day as parenteral is started) over
delayed initiation, and until the INR is 2.0 or above for at least 24 h
1B
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moderate to high 4 T score (scores of 4–8) serologic testing
should be performed, all heparin products must be dis-
continued and alternative anticoagulant therapy should be
initiated. If the diagnosis is confirmed with appropriate
serologic testing, HIT should be added to the problem list
and heparin to the allergy list in the patient’s electronic
health records and the patient should be educated to avoid
heparin. Patients with HIT-associated thrombosis require
anticoagulation therapy, typically for a period of
3–6 months. Warfarin should not be initiated until platelet
count recovery and should be overlapped with a parenteral
anticoagulant until the INR reaches the therapeutic range.
The reader is referred to a recent review on HIT for more
details on patient management [55]. Development and
implementation of HIT guidelines may improve the out-
comes of those with HIT, reduce unnecessary alternative
anticoagulant use, decrease cost and improve anticoagulant
safety [56].
Guidance Statement We suggest protamine sulfate be
administered to reverse the effect of heparin when indi-
cated. We suggest that health systems develop and imple-
ment guidelines on anticoagulant reversal and HIT
evaluation and management.
Guidance
LMWH for the treatment of acute VTE
(1) How should LMWH be initiated, including baseline
laboratory tests and dosing?
Enoxaparin (Lovenox) and dalteparin (Fragmin) are the
LMWHs available in the US. Enoxaparin is approved for
inpatient treatment of acute DVT with or without PE and
for outpatient treatment of acute DVT without PE using
1 mg/kg SQ q12 h or 1.5 mg/kg q24 h [57]. Dalteparin is
approved for VTE in patients with cancer at a dose of 200
units/kg SQ q24 h [58]. Dosing is generally based on total
body weight and renal function, evaluated using the
Cockcroft-Gault method, further influences dosing
requirement [59].
Use of enoxaparin 1.5 mg/kg once daily for the treatment
of VTE is controversial. This dosing option is based on a
single randomized, clinical trial comparing unfractionated
heparin (UFH) to enoxaparin 1.5 mg/kg daily or 1 mg/kg
twice daily in 900 patients with VTE [43]. While there was
no difference in recurrent VTE or major bleeding between
the groups as a whole, only 32 % of the patients enrolled had
PE at the time of randomization. Patients with symptomatic
PE, obesity and malignancy all had higher rates of recurrent
VTE when treated with 1.5 mg/kg daily versus 1 mg/kg
twice daily. Current guidelines suggest thatwhen enoxaparin
is used for the treatment of VTE, it should be dosed at 1 mg/
kg twice daily and that the reduced dose delivered by 1.5 mg/
kg once daily be avoided [11, 60].
Limiting dalteparin to the treatment of cancer-associated
VTE is not necessary. Dalteparin is highly effective for the
treatment of VTE in patients without malignancy using 200
units/kg once daily or 100 units/kg twice daily as deter-
mined in a number of clinical trials [11, 61, 62].
Although the risk of HIT with LMWH is lower than
with UFH, a baseline platelet count is recommended as a
basis from which to consider the development of HIT. Re-
exposure to LMWH should be avoided in a patient with a
known history of HIT [63].
Therapy should be initiated as soon as possible, as
long as it is determined that fibrinolytics are not going to
Table 4 Transitions from parenteral to oral anticoagulants in the treatment of VTE




Required Required Not required
From heparin Start warfarin and heparin
concurrently
Start heparin alone Stop heparin
Continue heparin for a
minimum of 5 days AND
until INR[ 2.0
After a minimum of 5 days of heparin, start
dabigatran or edoxaban and stop heparin







Start LMWH/fondaparinux alone Stop LMWH/fondaparinux




minimum of 5 days AND
until INR[ 2.0
Give first dose of dabigatran or edoxaban at
the time the next dose of
LMWH/fondaparinux would have been
given
Give first dose of rivaroxaban or apixaban at
the time the next dose of
LMWH/fondaparinux would have been
given
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be administered for acute VTE. A pre-treatment hemo-
globin and/or hematocrit are used as a baseline from
which to assess subsequent changes that may reflect
bleeding. Finally, an elevated pre-treatment PT or aPTT
may detect the presence of an underlying coagulation
defect.
Guidance Statement We suggest that total body weight,
baseline serum creatinine, CBC, PT and aPTT be obtained
prior to initiating LMWH. We suggest that when enoxa-
parin is used for the treatment of VTE, only the twice daily
dosing strategy be used, except in patients with severe
renal insufficiency (see below). Further, we suggest that
once daily dalteparin can be used for the treatment of both
cancer- and non-cancer-associated VTE.
(2) What weight should be used to calculate dosing, and
should obese and low body weight patients be trea-
ted differently?
In clinical trials evaluating the effectiveness and safety
of LMWH for the treatment of VTE, total body weight has
been used to calculate dosing. While data evaluating the
safety and efficacy of LMWH in VTE patients with
extremes of weight is limited, total body weight is recom-
mended for LMWH dosing [59]. Due to concerns that
dosing based on total body weight may lead to over-anti-
coagulation in obesity, dose capping has been suggested and
is recommended in the product information for dalteparin.
However, several studies show little to no accumulation in
patients given uncapped doses with body weights up to
190 kg with dalteparin and 159 kg with enoxaparin [59,
64]. In addition, limiting the dose of LMWH by using dose
capping may result in inadequate anticoagulation and an
increased risk of recurrent VTE [65].
Pharmacodynamic studies involving LMWHs have
included patients weighing up to 190 kg, and the maximum
weight of patients enrolled in clinical trials is 196 kg [64,
66]. In a retrospective cohort of 300 patients receiving
enoxaparin for VTE treatment, the incidence of bleeding
events was similar between patients with a BMI C 40 kg/
m2; (maximum 66.4 kg/m2) and non-obese patients (29 %
vs. 23.1 %, p = 0.43) [67]. A multivariate analysis con-
cluded that obesity was not associated with an increased
risk of bleeding. The average dose of enoxaparin was
clinically similar between the groups (0.98 mg/kg vs.
1.04 mg/kg) with the majority of patients receiving twice
daily dosing (97 % and 91.5 % respectively). The inci-
dence of new thromboembolic events was statistically
similar (3.5 % vs. 2 %, p = 0.72).
As noted previously, a subgroup analysis from a retro-
spective study suggested that VTE may recur more often in
overweight and obese patients (BMI[ 27 kg/m2) treated
with enoxaparin once daily compared to twice daily (7.3 %
vs. 3.4 %; OR 4.0 [CI 1.08–15]) [43]. This difference may
reflect the benefits of a higher total daily dose with the
twice daily regimen. A retrospective study of 193 patients
weighing[90 kg treated with dalteparin 200 International
units/kg total body weight for VTE revealed only 2 major
bleeding events which were deemed unlikely to be caused
by dalteparin [68].
There are limited data on dosing LMWH in patients
with low body weight. The lowest body weight reported in
an enoxaparin VTE clinical trial was 44 kg and patients
\40 kg were excluded from the major dalteparin VTE
clinical trial [43, 69]. A registry of 7962 patients receiving
LMWH for acute VTE analyzed clinical outcomes based
on weight ranges: (less than 50 kg vs. 50–100 kg, vs.
greater than 100 kg] [17]. The majority of patients weighed
between 50–100 kg; only 242 patients weighed[100 kg
and only 161 patients weighed \50 kg. Compared to
patients weighing 50–100 kg, patients\50 kg had a sig-
nificant increase in the incidence of major bleeding (3 %
vs. 1.3 %) and minor bleeding (5.3 % vs. 2.5 % [OR 2.2;
95 %CI 1.2–4]). Mean daily doses were significantly
higher in the \50 kg group with 54 % receiving [200
international units/kg daily. The incidence of recurrent
VTE was similar between the \50 kg and 50–100 kg
groups. Patients[100 kg experienced similar bleeding and
thromboembolic complications compared with the
50–100 kg group.
For patients weighting[190 kg, peak anti-Xa monitor-
ing has been suggested [59]. However, an open label
prospective trial in 233 patients showed that mean peak
anti-Xa levels were similar between obese and healthy
weight individuals receiving enoxaparin 1.5 mg/kg once
daily or 1 mg/kg twice daily [70] and peak anti-Xa levels
have not been correlated with effectiveness (see below).
Guidance Statement We suggest that in all patients,
including underweight and obese, LMWH dosing should be
based on total body weight. For patients\40 kg, UFH may
be more appropriate. For enoxaparin dosing in obese
patients, 1 mg/kg BID is preferred over 1.5 mg/kg daily.
Dose capping should be avoided. Routine monitoring of
peak anti-Xa levels is not suggested in patients on LMWH,
whether obese or non-obese.
(3) How should patients with renal impairment be
treated?
LMWHs are cleared renally. There is an inverse rela-
tionship between CrCl and anti-Xa levels, with accumu-
lation of anti-Xa activity at the end of the dosing interval as
renal function declines [12, 71, 72].
Enoxaparin appears to be more dependent on renal
function for elimination than is dalteparin [73]. Product
information for enoxaparin includes a dose reduction to
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1 mg/kg daily for patients with CrCl\ 30 mL/min [57]. A
pharmacokinetic study showed that using this reduced dose
of enoxaparin resulted in 74 % of peak anti-Xa levels being
within an expected range of values [74]. After repeated
dosing, higher peak anti-Xa levels were reported in patients
receiving enoxaparin 1 mg/kg BID compared to 1.5 mg/kg
daily in both moderate (CrCl 30–50 mL/min) and severe
(CrCl\ 30 mL/min) renal dysfunction, indicating greater
accumulation with the BID regimen in renal insufficiency
[70].
In comparison, dalteparin product information includes
no dose adjustment for patients with severe renal impair-
ment, and recommends to use with caution and ‘‘monitor
anti-Xa levels’’ in patients with CrCl\ 30 mL/min) [58].
One prospective study evaluating dalteparin 100 Interna-
tional units/kg every 12 h found no difference in peak anti-
Xa levels in patients with CrCl\ 40 mL/min compared to
patients with normal renal function (0.47 U/mL vs. 0.55
U/mL, p[ 0.5.) [75].
Compared to patients with normal renal function, the risk
of major bleeding increases in patients with renal insuffi-
ciency exposed to LMWH. In a prospective registry of 1037
patients on LMWH, patients with CrCl\ 30 mL/min had an
increased incidence of major bleeding (7.3 % vs. 2.3 %;
p\ 0.001) [76]. A systematic review and meta-analysis of
18 LMWH studies (4971 patients) showed that patients with
CrCl B 30 mL/min had a significant increase in major
bleeding compared to patientswithCrCl[ 30 mL/min (5 %
vs. 2.4 %; odds ratio 2.25 [95 % CI, 1.19–4.27]; p = 0.013)
[72]. Fifteen of the 18 studies evaluated enoxaparin and
seven of those involved the use of therapeutic dosing rather
than dosing for VTE prophylaxis. When data were analyzed
based on LMWH preparation, major bleeding was increased
with standard dose enoxaparin (8.3 % vs. 2.4 %; odds ratio,
3.88 [CI 1.78–8.45]) but notwhen dosewas adjusted forCrCl
(0.9 %vs. 1.9 %; odds ratio, 0.58 [CI, 0.09–3.78] p = 0.23).
There were no data on bleeding associated with the use of
dalteparin.
An increased risk of bleeding has also been observed in
patients with moderate renal impairment. A retrospective
study compared major bleeding in patients receiving
treatment dose enoxaparin with normal renal function
(CrCl[ 80 mL/min) and moderate renal impairment (CrCl
30–50 mL/min) [77]. The incidence of major bleeding was
5.7 % with normal renal function compared to 22 % with
moderate renal impairment, unadjusted odds ratio of 4.7
(95 % CI, 1.7–13; p = 0.002). A dose reduction for
enoxaparin use in patients with mild or moderate renal
impairment (CrCl 30–80 mL/min) has not been
established.
Extended use ([10 days) of enoxaparin in patients with
renal insufficiency may require trough anti-Xa measure-
ment and dose adjustments if accumulation is noted. More
data on dose adjustment in renal impairment are needed.
One clinical approach to dosing enoxaparin in renal
insufficiency is to utilize manufacture dose recommenda-
tions for CrCl\ 30 mL/min but avoid LMWH if the
CrCl\ 20 mL/min [59].
LMWH is routinely avoided in patients on renal
replacement therapy (RRT) because of the numerous
variables that can affect clearance (filter type, interruption,
regimen change). LMWH dose adjustments for RRT are
not well defined [59].
Guidance Statement When LMWH is used for acute
treatment of VTE in patients with renal impairment, we
suggest that vigilant attention to potential bleeding risk
and monitoring for signs and symptoms of bleeding be
employed. Renal function should be estimated using the
Cockcroft-Gault method for calculating CrCl. In patients
with a CrCl\ 30 mL/min the use of UFH may be preferred
over LMWH and if enoxaparin is used, it should be dosed
at 1 mg/kg daily. If LMWH is used for an extended period
beyond the usual 5–7 days of treatment, trough anti-Xa
measurement may be considered in patients with severe
renal dysfunction. LMWH should be avoided in patients
with CrCl\ 20 mL/min and those receiving renal
replacement therapy.
(4) How should routine treatment be monitored?
LMWHs have predictable pharmacodynamic profiles and
wide therapeutic windows that do not require routine coag-
ulation monitoring in clinically stable and uncomplicated
patients. There are currently no commercial assays available
for LMWH. PT and aPTT are insensitive measures of
LMWH activity. Anti-Xa activity is a surrogate marker that
measures the anticoagulant effect of LMWH and is assumed
to correlate with hemorrhagic and thromboembolic events.
While LMWH anti-Xa concentrations may be helpful in
evaluating dosing in special patient populations, routine
LMWH anti-Xa monitoring is unnecessary and potentially
harmful if misinterpreted [12, 59, 78].
Although the risk of HIT is\ 1 % in patients on
LMWH, the consequences of HIT can be devastating.
Therefore, in patients with acute VTE, we suggest that a
baseline platelet count be obtained prior to initiation of
LMWH, and occasionally during the first 2 weeks of
LMWH use. Circulating HIT antibodies may remain pre-
sent for a median of 50–85 days depending on assay per-
formed and re-exposure can lead to a large decrease in
platelet count within 24 h. Therefore, in patients recently
treated with heparin/LMWH, a baseline platelet count
should be obtained prior to initiating LMWH and repeated
24 h later [63].
LMWHs are excreted by the kidney and accumulation
may occur in renal impairment. Occasional monitoring of
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renal function using serum creatinine, and calculation of
CrCl using the Cockcroft-Gault method may be useful to
assess changes in renal function that may indicate the need
for a dosing adjustment.
Guidance Statement We suggest all patients receiving
LMWH be monitored for signs and symptoms of bleeding
and be observed for changes in renal function that may
require a dose adjustment. We suggest against the routine
use of LMWH anti-Xa monitoring. CBC, platelet count and
Scr should be assessed periodically during LMWH
treatment.
(5) Is there a role for peak anti-Xa monitoring and for
trough anti-Xa monitoring?
The clinical trials evaluating LMWH did not use anti-Xa
levels to guide dosing and anti-Xa levels have not been eval-
uated in large studies. Although anti-Xa levels have been used
as amarker ofLMWHactivity they are not routinely evaluated
in clinically stable or uncomplicated patients. The interpreta-
tion of anti-Xa levels depends on the dose and time of last
LMWH administration. Trough anti-Xa levels may be used to
evaluate accumulation of anticoagulant effect at the end of
dosing interval. The value of peak anti-Xa levels is less clear.
Peak levels occur 3–5 h after a LMWH dose and if obtained,
should be measured at steady state [12, 79]. In a retrospective
review, the majority of anti-Xa levels were drawn inappro-
priately, limiting their utility for interpretation [68].
Data supporting a relationship between elevated
LMWH anti-Xa levels and bleeding are quite limited and
include a study in which dalteparin was administered by
continuous infusion and bleeding was increased in those
with mean levels above 0.8 u/mL [80, 81]. In the
uncommon situations in which anti-Xa activity is moni-
tored, it should be determined using a chromogenic
method and a calibration curve based on the LMWH used.
Target anti-Xa levels are not clinically validated, and there
is no standardized method for adjusting doses based on
anti-Xa level [59]. Peak anti-Xa levels observed in patients
treated with enoxaparin range from 0.6–1 IU/mL for twice
daily dosing and [1 IU/mL for once daily dosing. For
dalteparin, observed peaks may be somewhat higher sim-
ply because the total dose is given as a single injection
(200 units/kg SQ once daily) rather than divided into two
doses as in the case of enoxaparin (1 mg/kg SQ q12 h) [12,
79, 82]. Importantly, there are no data to suggest that
making dosing adjustments based on peak levels is corre-
lated with improved safety or efficacy.
While there is no consensus on an acceptable trough
anti-Xa level for treatment dose LMWH, at the end of the
12 or 24 h dosing interval, these values should not be
‘high’ [83]. In an acute coronary syndrome study, trough
anti-Xa levels[0.5 IU/mL were considered to be elevated
[84]. Elevated troughs reflect lack of LMWH clearance and
may suggest both an increased risk of bleeding and the
need for a prolonged dosing interval.
Trough anti-Xa concentrations may be helpful to eval-
uate the safety of LMWH dosing in special patient popu-
lations including patients with severe renal impairment
(although usefulness undetermined in patients on RRT) and
extremely low body weight [12, 59]. The role of peak anti-
Xa concentrations for evaluating efficacy in special popu-
lations including pregnancy and extremes of body weight is
not defined.
Guidance Statement We suggest that in limited popu-
lations, including patients with severe renal failure, trough
anti-Xa levels may have a role in evaluating LMWH
accumulation and the need to prolong the dosing interval.
We suggest that peak anti-Xa levels not be utilized to
evaluate dosing regimens in clinical practice.
(6) What is the appropriate duration of therapy when
transitioning to oral anticoagulant therapy?
Traditional anticoagulation involves concurrent initia-
tion of LMWH and warfarin on the same day, with con-
tinuation of LMWH for a minimum of 5 days and until the
INR is above 2.0 (see above and Table 3) [11] When
dabigatran or edoxaban are used for VTE treatment,
LMWH must be started first and continued for a minimum
of 5 days prior to initiation of these oral anticoagulants [47,
49, 50].
LMWH alone is an option for patients in whom INR is
difficult to control or in whom oral anticoagulation is not
an option, and is more effective than VKA therapy in
patients with cancer [69]. Several randomized, controlled
trials have evaluated the safety and efficacy of LMWH for
the full course of VTE treatment compared to traditional
short term LMWH followed by oral vitamin K antagonist
(VKA) therapy. Among trials with the highest method-
ological quality, a recent meta-analysis showed a non-
significant reduction in the odds of recurrent VTE (OR
0.80, 95 % CI 0.54–1.18) and in the odds of bleeding (OR
0.62, 95 % CI 0.36–1.07) favoring LMWH [85]. Never-
theless, oral anticoagulation remains a more common
approach due to the expense of LMWH and the need for
drug delivery by injection.
Guidance Statement Parenteral anticoagulation with
LMWH should be overlapped with warfarin for at least
5 days and until a single INR is 2.0 or greater. Treatment
of VTE with rivaroxaban and apixaban does not require
initial parenteral anticoagulation while dabigatran and
edoxaban require a minimum of 5 days of parenteral
anticoagulation prior to initiation. See Table 4 for addi-
tional details. The timing of the first dose of a TSOAC is
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based on when the next scheduled dose of LMWH would be
due.
(7) Which patients are acceptable candidates for outpa-
tient treatment of VTE with LMWH?
A number of randomized trials have compared outpa-
tient treatment of DVT with LMWH versus inpatient
treatment of DVT with either UFH or LMWH. A Cochrane
review of 6 randomized controlled trials including 1708
patients with DVT showed that outpatient therapy was
associated with a lower rate of recurrent VTE, reduced
mortality and no difference in minor bleeding [86].
While PE has historically been treated on an inpatient
basis, a systematic review and meta-analysis of 11 studies,
including 1258 patients, showed that low risk patients with
PE can safety be treated as outpatients [87]. Studies
included in the meta-analysis utilized either a risk stratifi-
cation method or clinical judgment to determine low risk
patients. The incidence of VTE recurrence and major
bleeding was low in the studies and the event rates between
the studies that used a risk stratification model versus
clinical judgment were similar. Approximately one-third to
one-half of acute PE patients may be classified as low-risk
[88].
Clinical prediction rules, including the Pulmonary
Embolism Severity Index (PESI) and Simplified PESI are
simple tools to identify low-risk PE patients (mortality
\1 %) with excellent negative predictive performance
[89]. In a randomized controlled trial, acute PE patients
with low risk PESI scores who were treated as outpatients
with enoxaparin 1 mg/kg twice daily had non-inferior
outcomes compared to those treated as inpatients [90].
Characteristics of patients who may be less suitable for
outpatient VTE management have been identified and
include body weight \70 kg, active malignancy, recent
immobility, chronic heart failure, renal insufficiency, and
bilateral DVT. In the REITE registry, these factors were
independently associated with an increased risk of symp-
tomatic PE, recurrent DVT, major bleeding or death [91].
In addition, DVT patients who may require hospitalization
include those with venous gangrene or extensive iliofe-
moral involvement, severe acute obstruction (phlegmasia
cerula dolens), poor social circumstances, active bleeding
or a high risk of bleeding, severe pain, renal impairment,
significant communication deficits or mobility problems
[11, 92]. Home circumstances for adequate outpatient
treatment include well-maintained living conditions, strong
support from family or friends, phone access and ability to
quickly return to hospital if there is clinical deterioration
[11].
Guidance Statement We suggest patients with VTE be
evaluated to determine treatment setting. Patients with
DVT and/or PE who are identified as having a low risk of
complications should be treated in the outpatient setting as
long as they have adequate home support.
(8) How should LMWH-induced over-anticoagulation,
thrombocytopenia and bleeding be managed?
The overall risk of major bleeding associated with
LMWH ranges from 1–4 % [93]. When significant bleeding
or over-anticoagulation occurs, LMWH should be discon-
tinued immediately. Observation without intervention is
appropriate if bleeding is not present as demonstrated in a
case series of intentional LMWH overdose [94]. Protamine
sulfate may be used as a reversal agent for LMWH, but only
reverses 60–80 % of the anticoagulant activity of LMWH.
While it fully reverses the anti-IIa fraction of LMWH, it
only partially reverses the anti-Xa component of LMWH
due to the reduced sulfate charge in the ultra-low molecular
weight heparin fragments present. Enoxaparin appears to be
less susceptible to protamine sulfate reversal than dalteparin
because its structure has less sulfonation [95].
There are limited clinical data on the use of protamine
sulfate to reverse LMWH [93, 96]. A retrospective, single
center study that evaluated the use of protamine sulfate to
emergently reverse LMWH found that 4 of 14 patients with
active bleeding continued to bleed or rebled after pro-
tamine administration [93]. No correlation was evident
between anti-Xa levels and bleeding cessation.
The need for and dose of protamine sulfate is based on
the timing of the last dose of LMWH, the severity of
bleeding and the estimated clearance of LWMH based on
the patient’s renal function. In patients with impaired renal
function the anticoagulant effect of LMWH may persist
and the treatment window for protamine sulfate may be
extended. Current guidelines suggest that if LMWH was
given within the previous 8 h, protamine sulfate may be
administered in a dose of 1 mg per 100 anti-Xa units of
LMWH up to a maximum single dose of 50 mg (1 mg of
enoxaparin equals approximately 100 anti-Xa units) [12].
A second dose of 0.5 mg protamine sulfate per 100 anti-Xa
units should be administered if bleeding continues or if the
aPTT is prolonged 2–4 h after the initial protamine dose. A
lower initial dose of protamine sulfate (0.5 mg per 100
anti-Xa units) may be administered if the time since
LMWH administration is greater than 8 h. If greater than
12 h has elapsed since administration of LMWH, pro-
tamine sulfate may not be effective and supportive mea-
sures to control bleeding should be used.
The risk of HIT is lower for LMWH than for UFH [55].
Nevertheless, if thrombocytopenia or thrombosis develops
during LMWH treatment, the patient should be evaluated
for HIT as outlined previously for UFH, and treated
according to current guidelines [55].
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Guidance Statement We suggest that protamine sulfate
be used to reverse LWMH if major bleeding occurs. The
timing of the lastdose of LMWH should be assessed when
determining if protamine sulfate should be administered
and theappropriate dose to be administered. A repeat dose
of protamine may be administered if bleeding continues
orif the aPTT is prolonged 2–4 h after the initial dose.
Patients who develop HIT in response to LMWH should be
treatedaccording to current guidelines for HIT.
Guidance
Fondaparinux for the treatment of acute VTE
(1) How should fondaparinux be initiated, including
baseline labs and dosing?
The clinical evidence supporting the efficacy and safety
of fondaparinux in the treatment of VTE comes from the
MATISSE trials. In the MATISSE-DVT trial, patients
(n = 2205) with acute symptomatic DVT were randomized
in a double-blinded fashion to SC fondaparinux or SC
enoxaparin overlapping with a VKA for at least 5 days and
until an INR of greater than 2.0 was achieved [97]. Fonda-
parinux was dosed based on weight terciles. Patients
weighing 50–100 kg received 7.5 mg once daily, while
patients weighing less than 50 kg received 5 mg once daily,
and those weighing more than 100 kg received 10 mg once
daily. Enoxaparin was dosed at 1 mg/kg twice daily.
In the MATISSE-PE trial, patients (n = 2213) with
acute symptomatic PE were randomized in an open-label
fashion to SC fondaparinux as dosed in the MATISSE-
DVT trial, or intravenous (IV) UFH with an initial bolus of
at least 5000 units and an initial infusion of at least 1250
units per hour to achieve and maintain an aPTT of 1.5–2.5
times control [98]. Both parenteral agents were to be
overlapped with a VKA for at least 5 days and until an INR
of greater than 2.0 was achieved.
In the MATISSE-DVT trial, fondaparinux was non-infe-
rior to enoxaparin with respect to the primary endpoint of
recurrent VTE at 3 months (3.9 % vs. 4.1 %) [97]. Major
bleeding was also not different between fondaparinux and
enoxaparin (1.1 % vs. 1.2 %). In the MATISSE-PE trial,
fondaparinux was found to be non-inferior compared to IV
UFH in preventing the primary endpoint of symptomatic PE
and new or recurrent DVT at 3 months (3.8 % vs. 5.0 %)
[98]. Major bleeding was also similar between the groups
(1.3 % vs. 1.1 %). In both studies, mortality did not differ
between the groups.
Therapy should be initiated as soon as possible and it is
determined that fibrinolytics are not going to be adminis-
tered. A baseline weight is required to determine the
correct dose of fondaparinux. A baseline SCr and CrCl
should be calculated since fondaparinux is contraindicated
in patients with a CrCl of less than 30 mL/min. A baseline
CBC should also be evaluated. An elevated pre-treatment
PT or aPTT may detect the presence of an underlying
coagulation defect.
Guidance Statement We suggest that total body weight,
baseline serum creatinine, CBC, PT and aPTT be obtained
prior to initiating fondaparinux therapy. We suggest dosing
fondaparinux based on weight as follows: less than 50 kg:
5 mg SC once daily, 50–100 kg: 7.5 mg SC once daily, and
greater than 100 mg: 10 mg SC once daily.
(2) What weight should be used to calculate dosing, and
should obese and low body weight patients be trea-
ted differently?
In the MATISSE trials, total body weight was used to
calculate dosing of fondaparinux [97, 98]. In the combined
MATISSE trials, 496 (11 %) of patients enrolled weighed
more than 100 kg, and 251 of them received fondaparinux
[99]. In patients weighing 100 kg or less, the incidence of
recurrent VTE occurred in 3.9 % of patients receiving
fondaparinux compared to 4.4 % with heparin (p = 0.42).
In patients weighing more than 100 kg, the rate of recurrent
VTE in patients receiving fondaparinux 10 mg SC once
daily was 4.0 % compared to 5.7 % in patients receiving a
heparin (p = 0.41). Major bleeding events occurred
numerically less frequently in patients receiving fonda-
parinux 10 mg compared to other doses (0.4 % vs. 1.3 %)
and was not different compared to patients weighing more
than 100 kg receiving a heparin (0.4 % vs. 0.8 %;
p = 0.62). A similar analysis was conducted in the 1216
patients (28 %) in the MATISSE trials with a BMI of 30 or
more [99]. The rate of recurrent VTE was non-inferior with
fondaparinux compared with heparin in both non-obese
(3.9 % vs. 4.5 %; p = 0.42) and obese (3.7 % vs. 4.8 %;
p = 0.40) patients. As with body weight, the efficacy of
fondaparinux appeared to be similar regardless of BMI.
Major bleeding rates were also not different between
patients receiving fondaparinux and a heparin in non-obese
(1.5 % vs. 1.2 %; p = 0.53) and obese (0.3 % vs. 1.1 %;
p = 0.18) patients. The median weight in those over
100 kg in the MATISSE trials was 110 kg, with the
heaviest patient weighing 175.5 kg. The median BMI in
those with a BMI of 30 or more was 33 kg/m2, with the
highest being 80.3 kg/m2. Based on these data, there does
not seem to be any reason to treat heavier or obese patients
with doses greater than 10 mg.
Data on low body weight patients are more limited. There
were only a total of 102 (2.3 %) patients in the combined
MATISSE trials with a body weight of less than 50 kg [97,
98]. The rate of recurrent VTE in the fondaparinux and
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heparin groups were similar (11.3 % vs. 14.3 %), but about
3-fold higher than the rates in the overall study (about 4 %).
At first glance it may be interpreted that 5 mgmay have been
an insufficient dose, but rates were similar in the heparin
arms. It should also be noted that the numbers are quite small
(6 events for fondaparinux vs. 7 events for a heparin) and
should be interpreted with caution. Major bleeding rates
were consistently low for both the fondaparinux and heparin
group (1.9 % vs. 2.0 %).
Guidance Statement We suggest patients be dosed
based on total body weight. Patients weighing more than
100 kg should receive fondaparinux 10 mg SC once daily.
Patients with a BMI greater than 30 kg/m2 should be dosed
based on total body weight. Patients weighing less than
50 kg should receive 5 mg SC once daily.
(3) How should patients with renal impairment be
treated?
Fondaparinux is eliminated almost completely through
the kidney as unchanged drug. Patients with a Scr greater
than 2.0 mg/dL (177 lmol/L) were not included in the
MATISSE trials [97, 98]. There were 51 (2.3 %) patients
randomized to fondaparinux with a CrCl less than 30 mL/
min enrolled in the MATISSE trials. In these patients, there
were 4 major bleeding events (7.8 %) [97, 98].
Fondaparinux clearance is reduced by 25 % in patients
with moderate renal insufficiency (CrCl 30–60 mL/min)
[100]. Therefore, there could be some drug accumulation in
these patients with longer than usual courses of therapy. It
may be appropriate tomonitor a trough fondaparinux anti-Xa
to assess accumulation in patients receiving treatment dose
for more than 10 days. While some lower dose trials have
been conducted in the area of VTE prophylaxis in patients
with a CrCl of 20–50 mL/min [100, 101] fondaparinux
should be avoided in patients with a CrCl of less than 30 mL/
min for treatment of VTE until more data become available.
According to the manufacturer, fondaparinux is contraindi-
cated in patients with a CrCl of less than 30 mL/min.
Guidance Statement We suggest that fondaparinux be
avoided in patients with a CrCl of less than 30 mL/min. We
also suggest that patients with moderate renal insufficiency
be monitored closely for bleeding during longer durations
of therapy due to potential accumulation.
(4) How should treatment be monitored?
Due to the predictable pharmacokinetic and pharmaco-
dynamic profile of fondaparinux, routine coagulation
monitoring is not necessary. As with any anticoagulant, the
most common adverse effect is bleeding. Therefore, mon-
itoring for signs and symptoms of bleeding is paramount.
The need for platelet count monitoring is uncertain.
Fondaparinux has a limited impact on the PT or aPTT,
even at high doses [102]. The mean increase in the PT at
therapeutic levels of fondaparinux (0.8 lg/mL) was only
about 1.2 s. Even at supratherapeutic levels (2 lg/mL) the
PT only increased 1.8 s above baseline. The mean increase
in the aPTT was only 4.6 s at therapeutic levels of fon-
daparinux, and 6.2 s with supratherapeutic levels. There-
fore, these assays are not appropriate for measuring
fondaparinux therapy.
Guidance Statement We suggest that most patients
receiving fondaparinux do not require therapeutic drug
monitoring. If the clinical setting suggests the need to assess
accumulation of fondaparinux, we suggest using an anti-Xa
assay calibrated for fondaparinux, and we suggest against
the use of a PT, aPTT, or activated clotting time (ACT).
(5) Is there a role for peak anti-Xa monitoring and for
trough anti-Xa monitoring?
Most patients receiving fondaparinux should not receive
anti-Xa monitoring. While fondaparinux provides a pre-
dictable anticoagulant response, there may be special sit-
uations in which measuring plasma concentrations may be
helpful. While evidence to support measuring plasma
concentrations is lacking, concentrations may be helpful to
guide therapy in patients on long-term therapy, or with
sudden changes in renal function, extremes in body weight,
or pregnancy. However, there are no data to suggest that
dosing adjustments in response to known plasma concen-
trations have any influence on patient outcomes.
A chromogenic anti Xa assay calibrated with fonda-
parinux produces reliable and reproducible results [102–
105]. Fondaparinux needs to be used to form the standard
curves to measure fondaparinux levels [12]. Results
obtained using a LMWH standard curve are less accurate
and standard curves using UFH are completely inaccurate
and should not be used [102, 106]. Peak anti-Xa levels
are typically achieved in 3 h after dosing [107]. Target
anti-Xa levels for fondaparinux are not established;
however peak anti-Xa levels in patients receiving treat-
ment doses of fondaparinux range from 0.6 to 1.5 lg/mL
and are typically in the range of 1.20–1.26 lg/mL.
Observed trough levels in patients receiving fondaparinux
are in the range of 0.46–0.62 lg/mL [12, 104, 108].
Importantly, these are observed values, not a ‘‘target
range’’ and have not been correlated with clinical
outcomes.
Guidance Statement If the clinical setting suggests a
benefit of measuring trough fondaparinux levels, we suggest
a chromogenic anti-Xa with the standardization curve cali-
brated with fondaparinux. We suggest against using anti-Xa
with the standard curves created using a LMWH or UFH.
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(6) What is the appropriate duration of therapy when
transitioning to oral anticoagulant therapy?
The duration of fondaparinux therapy when transition-
ing to a VKA is similar to that with UFH or a LMWH
(Table 3). In the MATISSE trials, fondaparinux was
overlapped with a VKA for at least 5 days and until an INR
of greater than 2.0 was achieved. The mean duration of
overlap was 7 days [97, 98].
If fondaparinux is administered to a patient who will be
transitioned to a TSOAC, the oral agent should be initiated
at the time that the next fondaparinux dose would have
been given. See above and Table 4 for additional details.
Guidance Statement Parenteral anticoagulation with
fondaparinux should be overlapped with warfarin for at least
5 days and until a single INR is 2.0 or greater. Treatment of
VTE with rivaroxaban and apixaban does not require initial
parenteral anticoagulation while dabigatran and edoxaban
require a minimum of 5 days of parenteral anticoagulation
prior to initiation. See Table 4 for additional details. The
timing of the first dose of a TSOAC is based on when the next
scheduled dose of fondaparinux would be due.
(7) Who is a candidate for outpatient treatment of VTE
with fondaparinux?
In the MATISSE-DVT trial, 88 patients (8.1 %) were
treated with fondaparinux completely on an out-patient
basis, and 253 patients (23.2 %) received at least 3 days of
outpatient therapy. These numbers were similar to the
enoxaparin patients treated as outpatients (8.3 % and
25.2 %, respectively) [10]. In patients receiving some
outpatient therapy, the rate of recurrent VTE was similar
between the fondaparinux and enoxaparin groups (2.0 %
vs. 4.3 %) and was similar to the event rates for the overall
study. Major bleeding was also similar between groups
(1.5 % vs. 0.8 %) and similar to the bleeding rates in the
overall study. In the MATISSE-PE trial, 158 (14.5 %) of
patients randomized to fondaparinux received some portion
of their fondaparinux treatment on an outpatient basis [98].
The rate of recurrent VTE was 3.2 % and there were no
major bleeding events in these patients. These values are
similar to those in the overall study.
Outpatient treatment with fondaparinux has demon-
strated similar efficacy and safety to inpatient treatment of
VTE. Therefore, patients who would be considered out-
patient candidates for LMWH therapy should also be
considered outpatient candidates for fondaparinux.
Guidance Statement We suggest patients with VTE be
evaluated to determine the treatment setting. Patients with
DVT and/or PE who are identified as having a low risk of
complications (see above) should be treated in the outpatient
setting as long as they have adequate home circumstances.
(8) Can fondaparinux be used for VTE treatment in the
presence of active HIT or those with a history of HIT?
Due to the smaller size of the molecule and low affinity
for platelet factor 4, fondaparinux does not cross react with
HIT antibodies [109]. While there have been a small
number of case reports of fondaparinux-associated HIT
with the use of fondaparinux for VTE prevention [110–
112], no cases of HIT have been reported in any of the
major clinical trials evaluating the efficacy and safety of
fondaparinux in the prevention of VTE, the treatment of
VTE, or in treatment of patients with acute coronary syn-
drome. More data exist for the ability of fondaparinux to be
used in the treatment of HIT or as a safe alternative in those
with a history of HIT [113]. A number of case reports and
case series support the potential role of using fondaparinux
in the treatment of HIT [114–116]. These reports comprise
over 70 patients who developed HIT after treatment with
UFH and/or a LMWH for VTE prophylaxis. Fondaparinux
doses varied from 2.5 to 15 mg daily.
In the only prospective study in the literature, 7 patients
with acute HIT were treated with fondaparinux and com-
pared to 10 similar historical control HIT patients from the
same hospital [117]. Patients presenting with thrombosis (6
of the 7) received treatment doses of fondaparinux based on
weight as in theMATISSE trials, while the patient presenting
without thrombosis received 2.5 mg of fondaparinux SC
once daily. Historical controls received an injectable direct
thrombin inhibitor via the hospital’s protocol. Eight of the 10
historical control patients presented with thrombosis. All
fondaparinux patients experienced platelet count recovery
compared to 8 of the 10 historical controls. There were no
new thromboses, major bleeding events, or death in the
fondaparinux treated patients. There were 2 deaths in the
historical control patient group.
One benefit of fondaparinux over direct thrombin inhi-
bitors for treating HIT is that clinicians do not need to be
concerned with PTT confounding which is defined as ‘‘a
situation where an underlying patient-related clinical factor
(or factors) results in anticoagulant related changes in PTT
values that are misleading with respect to indicating a
patient’s true level of anticoagulation [118]. PTT con-
founding can be caused by disseminated intravascular
coagulation, hepatic failure, VKA use and lupus antico-
agulant. With PTT confounding, patients on DTIs appear
supratherapeutic with high aPTTs and as a result DTI
therapy is held or reduced. Progressive thrombosis then
ensues while the aPTT remains elevated. Although fon-
daparinux may offer a benefit, its long elimination half-life,
dependence on renal function for elimination and non-re-
versibility must be considered.
In the most recent guidelines from ACCP, fonda-
parinux is mentioned as an option for the treatment of
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Table 5 Summary of guidance statements
Question Guidance statement
Heparin for treatment of acute VTE
(1) How should heparin be initiated, including baseline laboratory
tests and dosing?
We suggest that total body weight, CBC, PT and aPTT be obtained
prior to initiating heparin therapy. Heparin efficacy is related to dose
regardless of route. The initial dose is more important than the aPTT
in predicting efficacy. Although optimal initial dosing for bolus and
continuous infusion remain uncertain, we suggest doses outlined in
Table 2, acknowledging that these options have not been compared
in head-to-head clinical trials. Internal audits to determine the dose
requirement to produce therapeutic anticoagulation based upon the
responsiveness of the health-system’s aPTT reagent and coagulation
instrument are encouraged
(2) What weight should be used to calculate dosing, and should obese
and low body weight patients be treated differently?
When a weight based heparin dosing strategy is selected, we suggest
total body weight for calculating dose and encourage internal audits
of protocol performance. For the obese/morbidly obese patient either
total body weight or adjusted body weight can be used. Although no
increased risk of major bleeding has been reported when morbidly
obese patients are managed using total body weight, studies have not
included patients weighing above 270 kg. If adjusted body weight is
used, prompt attention to initial laboratory results is warranted to
ensure the therapeutic threshold is exceeded in a timely manner.
Empiric dose caps may increase the risk of initial under
anticoagulation in obese and morbidly obese patients. If empiric dose
caps are used, individualized initial dosing should be available for
obese and morbidly obese patients
(3) How should heparin be monitored? The optimal approach to heparin monitoring is unknown. Either aPTT
or heparin anti-Xa level monitoring may be used. We suggest using
anti-Xa level monitoring in patients with heparin resistance, a
prolonged baseline aPTT or altered heparin responsiveness. We
suggest the aPTT or anti-Xa level be checked every 6 h until two
consecutive therapeutic results are obtained, after which the
frequency of monitoring can be extended to once daily
(4) What data support the benefit of monitoring? The benefit of monitoring IV heparin once a therapeutic threshold has
been exceeded is not well defined. We suggest monitoring of
continuous infusion heparin therapy, either using aPTT or anti-Xa, as
this is considered standard of care despite the weak evidence base.
Monitoring is optional in those receiving SC weight-based heparin
therapy
(5) What is the appropriate therapeutic range? The optimal heparin therapeutic range is uncertain. The target
therapeutic range is less important than ensuring an appropriate
initial heparin dose. The CAP recommends the one-time
establishment of a heparin concentration-derived aPTT therapeutic
range. The cumulative summation method is suggested for range re-
evaluation following reagent/instrument change. When anti-Xa
monitoring is used, a therapeutic target of 0.3–0.7 units/mL is
suggested
(6) When should heparin resistance be suspected? We suggest drawing a paired aPTT and heparin anti-Xa level when
heparin resistance is suspected. If the aPTT is subtherapeutic and the
anti-Xa level is therapeutic, the heparin dose does not require
adjustment and subsequent monitoring should occur using the anti-
Xa level when feasible. If, despite serial dose increases, both the
aPTT and anti-Xa level remain low, true heparin resistance may be
present
(7) What algorithm should be used for dosing adjustments? We recommend that heparin dosing be guided by a dose adjustment
nomogram, and that a weight based heparin dose adjustment
algorithm may offer benefit over a fixed adjustment algorithm for the
obese patient. More research in defining and assessing the optimal
dosage adjustment nomogram is needed




(8) What is the appropriate duration of therapy for heparin for
transition to oral anticoagulant therapy?
Parenteral anticoagulation with heparin should be overlapped with
warfarin for at least 5 days and until a single INR is 2.0 or greater.
Treatment of VTE with rivaroxaban and apixaban does not require
initial parenteral anticoagulation while dabigatran and edoxaban
requires a minimum of 5 days of parenteral anticoagulation prior to
initiation. See Table 4 for additional details
(9) How should heparin-induced over-anticoagulation,
thrombocytopenia and bleeding be managed?
We suggest protamine sulfate be administered to reverse the effect of
heparin when indicated. We suggest that health systems develop and
implement guidelines on anticoagulant reversal and HIT evaluation
and management
LMWH for treatment of acute VTE
(1) How should LMWH be initiated, including baseline laboratory
tests and dosing?
We suggest that total body weight, baseline serum creatinine, CBC, PT
and aPTT be obtained prior to initiating LMWH. We suggest that
when enoxaparin is used for the treatment of VTE, only the twice
daily dosing strategy be used, except in patients with severe renal
insufficiency (see below). Further, we suggest that once daily
dalteparin can be used for the treatment of both cancer- and non-
cancer-associated VTE
(2) What weight should be used to calculate dosing, and should obese
and low body weight patients be treated differently?
We suggest that in all patients, including underweight and obese,
LMWH dosing should be based on total body weight. For patients
\40 kg, UFH may be more appropriate. For enoxaparin dosing in
obese patients, 1 mg/kg BID is preferred over 1.5 mg/kg daily. Dose
capping should be avoided. Routine monitoring of peak anti-Xa
levels is not recommended in patients on LMWH, whether obese or
non-obese
(3) How should patients with renal impairment be treated? When LMWH is used for acute treatment of VTE in patients with renal
impairment, we suggest that vigilant attention to potential bleeding
risk and monitoring for signs and symptoms of bleeding be
employed. Renal function should be estimated using the Cockcroft-
Gault method for calculating CrCl. In patients with a CrCl\ 30 mL/
min the use of UFH may be preferred over LMWH and if enoxaparin
is used, it should be dosed at 1 mg/kg daily. If LMWH is used for an
extended period beyond the usual 5–7 days of treatment, trough anti-
Xa measurement may be considered in patients with severe renal
dysfunction. LMWH should be avoided in patients with
CrCl\ 20 mL/min and those receiving renal replacement therapy
(4) How should routine treatment be monitored? We suggest all patients receiving LMWH be monitored for signs and
symptoms of bleeding and be observed for changes in renal function
that may require a dose adjustment. We suggest against the routine
use of LMWH anti-Xa monitoring. CBC, platelet count and Scr
should be assessed periodically during LMWH treatment
(5) Is there a role for peak anti-Xa monitoring and for trough anti-Xa
monitoring?
We suggest that in limited populations, including patients with severe
renal failure, trough anti-Xa levels may have a role in evaluating
LMWH accumulation and the need to prolong the dosing interval.
We suggest that peak anti-Xa levels not be utilized to evaluate dosing
regimens in clinical practice
(6) What is the appropriate duration of therapy when transitioning to
oral anticoagulant therapy?
Parenteral anticoagulation with LMWH should be overlapped with
warfarin for at least 5 days and until a single INR is 2.0 or greater.
Treatment of VTE with rivaroxaban and apixaban does not require
initial parenteral anticoagulation while dabigatran and exoxaban
require a minimum of 5 days of parenteral anticoagulation prior to
initiation. See Table 4 for additional details. The timing of the first
dose of a TSOAC is based on when the next scheduled dose of
LMWH would be due
(7) Which patients are acceptable candidates for outpatient treatment
of VTE with LMWH?
We suggest patients with VTE be evaluated to determine treatment
setting. Patients with DVT and/or PE who are identified as having a
low risk of complications should be treated in the outpatient setting
as long as they have adequate home circumstances
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patients with HIT without thrombosis, as well as for use
in patients with a history of HIT who require anticoagu-
lation [63]. While the guidelines mention the limitations
of the data, it should be remembered that there are no




(8) How should LMWH-induced over-anticoagulation,
thrombocytopenia and bleeding be managed?
We suggest that protamine sulfate be used to reverse LWMH if major
bleeding occurs. The timing of the last dose of LMWH should be
assessed when determining if protamine sulfate should be
administered and the appropriate dose to be administered. A repeat
dose of protamine may be administered if bleeding continues or if the
aPTT is prolonged 2–4 h after the initial dose. Patients who develop
HIT in response to LMWH should be treated according to current
guidelines for HIT
Fondaparinux for treatment of acute VTE
(1) How should fondaparinux be initiated, including baseline labs and
dosing?
We suggest that total body weight, baseline serum creatinine, CBC, PT
and aPTT be obtained prior to initiating fondaparinux therapy. We
suggest dosing fondaparinux based on weight as follows: less than
50 kg: 5 mg SC once daily, 50–100 kg: 7.5 mg SC once daily, and
greater than 100 mg: 10 mg SC once daily
(2) What weight should be used to calculate dosing, and should obese
and low body weight patients be treated differently?
We suggest patients be dosed based on total body weight. Patients
weighing more than 100 kg should receive fondaparinux 10 mg SC
once daily. Patients with a BMI greater than 30 kg/m2 should be
dosed based on total body weight. Patients weighing less than 50 kg
should receive 5 mg SC once daily
(3) How should patients with renal impairment be treated? We suggest that fondaparinux be avoided in patients with a CrCl of less
than 30 mL/min. We also suggest that patients with moderate renal
insufficiency be monitored closely for bleeding during longer
durations of therapy due to potential accumulation
(4) How should treatment be monitored? We suggest that most patients receiving fondaparinux do not require
therapeutic drug monitoring. If the clinical setting suggests the need
to assess accumulation of fondaparinux, we suggest using an anti-Xa
assay calibrated for fondaparinux, and we suggest against the use of a
PT, aPTT, or ACT
(5) Is there a role for peak anti-Xa monitoring and for trough anti-Xa
monitoring?
If the clinical setting suggests a benefit of measuring trough
fondaparinux levels, we suggest a chromogenic anti-Xa with the
standardization curve calibrated with fondaparinux. We suggest
against using anti-Xa with the standard curves created using a
LMWH or UFH
(6) What is the appropriate duration of therapy when transitioning to
oral anticoagulant therapy?
Parenteral anticoagulation with fondaparinux should be overlapped
with warfarin for at least 5 days and until a single INR is 2.0 or
greater. Treatment of VTE with rivaroxaban and apixaban does not
require initial parenteral anticoagulation while dabigatran and
edoxaban require a minimum of 5 days of parenteral anticoagulation
prior to initiation. See Table 4 for additional details. The timing of
the first dose of a TSOAC is based on when the next scheduled dose
of fondaparinux would be due
(7) Who is a candidate for outpatient treatment of VTE with
fondaparinux?
We suggest patients with VTE be evaluated to determine the treatment
setting. Patients with DVT and/or PE who are identified as having a
low risk of complications (see above) should be treated in the
outpatient setting as long as they have adequate home circumstances
(8) Can fondaparinux be used for VTE treatment in the presence of
active heparin-induced thrombocytopenia (HIT) or those with a
history of HIT?
We suggest that fondaparinux may be used for treatment of VTE in
patients with a history of HIT. In patients with acute VTE who
develop HIT in response to initial use of UFH/LMWH, we suggest
that fondaparinux may be considered as an option for treatment.
When fondaparinux is used in patients with acute HIT, we suggest
that treatment doses be used
(9) How should fondaparinux-induced over-anticoagulation and
bleeding be managed?
We suggest the use of rFVIIa in the setting of life-threatening bleeding
induced by fondaparinux, and that potential benefits must be weighed
against thrombotic risk
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Guidance Statement We suggest that fondaparinux may
be used for treatment of VTE in patients with a history of
HIT. In patients with acute VTE who develop HIT in
response to initial use of UFH/LMWH, we suggest that
fondaparinux may be considered as an option for treat-
ment. When fondaparinux is used in patients with acute
HIT, we suggest that treatment doses be used.
(9) How should fondaparinux-induced over-anticoagu-
lation and bleeding be managed?
While protamine sulfate is effective at reversing the
anticoagulant effect of UFH and to some extent LMWH, it
is not effective in reversing fondaparinux [119]. Since
protamine does not bind to the low molecular weight
molecule due to the reduced sulfate charge of fondaparinux,
there is no reversal of the anticoagulant effect. Recombinant
activated factor VII (rFVIIa) is the most extensively studied
reversal agent for fondaparinux [120]. Healthy subjects who
received a single 10 mg SC dose of fondaparinux followed
by a single IV bolus of rFVIIa 90 lg/kg 2 h later demon-
strated normalization of thrombin-generation time and
endogenous thrombin potential for up to 6 h. Case reports
and case series also support a role for rFVIIa in stopping
fondaparinux-induced bleeding [121–123]. Available data
support the use of high dose rFVIIa at 90 lg/kg. The effi-
cacy of a lower and less expensive dose of 30 lg/kg is
unknown. The ability of concentrated clotting factors to
reverse the impact of fondaparinux on thrombin generation
test has been evaluated in one in vitro study [124]. In this
study, activated prothrombin complex concentrate (FEIBA-
NF) was able to correct the thrombin generation test, while
prothrombin complex concentrate (Kaskadil) and rFVIIa
were less effective. More data and experience with these
agents are needed, particularly considering the risk of
thrombosis associated with their use.
Guidance Statement We suggest the use of rFVIIa in
the setting of life threatening bleeding induced by fonda-
parinux, and that potential benefits must be weighed
against thrombotic risk.
Conclusion
Despite advances in the development of oral anticoagu-
lants, the parenteral heparins continue to be a component of
the treatment of VTE. Their appropriate use, particularly in
special populations, remains a challenge for clinicians.
Table 5 summarizes the guidance statements for the prac-
tical management of the heparin anticoagulants.
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